Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7409874 | 0.98 | ALDH1A1 (0.96) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| SCHEMBL3262128 | 0.98 | ALDH1A1 (0.96) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL23850789 | 0.92 | ALDH1A1 (0.85) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| SCHEMBL16226380 | 0.90 | ALDH1A1 (0.81) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| SCHEMBL11194277 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KDM4ESMN1; SMN2POLBKMT2A | |
| SCHEMBL30341108 | 0.85 | ALDH1A1 (0.73) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| SCHEMBL2096803 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| SCHEMBL14614566 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CYP2A13KDM4ESMN1; SMN2POLB | |
| SCHEMBL11196594 | 0.83 | ALDH1A1 (0.69) | ALDH1A1KDM4ESMN1; SMN2POLBKMT2A | |
| SCHEMBL8803732 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CYP2A13KDM4EPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-3083584-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-10-26 | — | — | EP | disclosed |
| EP-2897961-B1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015090232-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2012058127-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
| WO-2009120700-A2 | INHIBITION OF DCPS | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
| US-4234484-A | FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885CYP2A13 3044/4885KDM4E 2746/4885 |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885CYP2A13 3044/4885KDM4E 2746/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885CYP2A13 3044/4885KDM4E 2746/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | ALDH1A1 1243/4885CYP2A13 3044/4885KDM4E 2746/4885 |
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | ALDH1A1 358/4885CYP2A13 446/4885KDM4E 3528/4885 |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | ALDH1A1 1862/4885CYP2A13 2176/4885KDM4E 1873/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885CYP2A13 3044/4885KDM4E 2746/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | ALDH1A1 2797/4885CYP2A13 1014/4885KDM4E 1252/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | ALDH1A1 1243/4885CYP2A13 3044/4885KDM4E 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.